<DOC>
	<DOCNO>NCT00387920</DOCNO>
	<brief_summary>This phase I trial study side effect best dose sunitinib treat young patient refractory solid tumor . Sunitinib may stop growth tumor cell block enzyme need growth block blood flow tumor .</brief_summary>
	<brief_title>Sunitinib Treating Young Patients With Refractory Solid Tumors</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) recommend phase II dose sunitinib malate pediatric patient refractory solid tumor . II . Determine toxicity regimen patient . III . Characterize pharmacokinetics regimen patient . IV . Evaluate tolerability pharmacokinetic profile sunitinib malate capsule content sprinkle applesauce yogurt use recommend phase II dose . SECONDARY OBJECTIVES : I . Determine , preliminarily , antitumor effect regimen patient . II . Describe change peripheral blood monocyte count , circulate endothelial cell , plasma angiogenic factor treatment sunitinib malate . III . Explore change tumor vascular permeability use dynamic contrast-enhanced ( DCE ) -magnetic resonance imaging ( MRI ) patient receive sunitinib malate . OUTLINE : This multicenter , dose-escalation study ( part A ) follow pediatric-friendly formulation study ( part B ) . PART A : Patients receive oral sunitinib malate daily day 1-28 day . Treatment repeat every 42 day 18 course absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos sunitinib malate MTD determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . PART B : Patients receive sunitinib malate capsule content sprinkle applesauce yogurt daily day 1-28 . Treatment repeat every 42 day 18 course absence disease progression unacceptable toxicity . After first course , patient may switch capsule formulation convenience . NOTE : Patients receive sunitinib malate day 2 first course allow pharmacokinetic testing . Blood collect day 1 , 7 , 14 , 21 , 28 course 1 pharmacokinetic study use liquid chromatography/mass spectrometry . After completion study treatment , patient follow 30 day .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Germ Cell Embryonal</mesh_term>
	<mesh_term>Endodermal Sinus Tumor</mesh_term>
	<mesh_term>Choriocarcinoma</mesh_term>
	<mesh_term>Teratoma</mesh_term>
	<mesh_term>Germinoma</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Histologically confirm solid tumor ( required patient intrinsic brain stem tumor optic pathway glioma ) Recurrent refractory disease Measurable evaluable disease No known curative therapy therapy proven prolong survival acceptable quality life exist Patients metastatic bone marrow disease eligible evaluable hematologic toxicity Must refractory red blood cell platelet transfusion Primary CNS tumor know CNS metastasis allow Neurological deficit must relatively stable ≥ 1 week study enrollment No image evidence prior intracranial hemorrhage No evidence new CNS hemorrhage baseline MRI obtain within 14 day study enrollment ( ECHO gradient MRI sequence per institutional guideline require evaluation CNS hemorrhage ) The presence small punctuate CNS hemorrhage scan exclude patient participation No known bone marrow metastatic disease No tumor involve pleural surface Karnofsky performance status ( PS ) 50100 % ( &gt; 10 year age ) OR Lansky PS 50100 % ( ≤ 10 year age ) Absolute neutrophil count ≥ 1,000/mm³* Platelet count ≥ 100,000/mm³ ( transfusion independent ) * Hemoglobin ≥ 8.0 g/dL ( transfusion allow ) * Creatinine clearance radioisotope glomerular filtration rate ≥ 70 mL/min OR creatinine base age/gender follow : No great 0.8 mg/dL ( 2 5 year age ) No great 1 mg/dL ( 6 9 year age ) No great 1.2 mg/dL ( 10 12 year age ) No great 1.5 mg/dL ( male ) OR 1.4 mg/dL ( female ) ( 13 15 year age ) No great 1.7 mg/dL ( male ) OR 1.4 mg/dL ( female ) ( ≥ 16 year age ) Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ALT AST ≤ 2.5 time ULN ( ≤ 5 time ULN liver metastasis ) Albumin ≥ 2 g/dL LVEF shorten fraction normal Corrected QT interval ≤ 450 msec Amylase ≤ 1.5 time ULN Lipase ≤ 1.5 time ULN Body surface area ≥ 0.5 m² ( ≥ 0.4 m² part B ) Blood pressure within ULN Not pregnant nursing Fertile patient must use effective contraception No uncontrolled infection Able swallow sunitinib malate capsule ( part A ) No preexist thyroid abnormality ( hyper hypothyroidism ) unstable thyroid function No prior CNS hemorrhage No history allergic reaction attribute sunitinib malate component sunitinib malate capsule No allergy applesauce yogurt ( part B ) Recovered prior therapy No prior sunitinib malate No prior anthracycline ( dose ) No prior radiotherapy radiation field include heart ( include total body craniospinal irradiation ) At least 3 month since prior stem cell transplantation rescue ( without totalbody irradiation ) evidence graftvshost disease At least 2 week since prior local , palliative , smallport radiotherapy ( least 6 month radiation ≥ 50 % pelvis ) At least 6 week since prior substantial bone marrow radiotherapy At least 3 week since prior myelosuppressive therapy ( 6 week nitrosoureas ) At least 1 week since prior antineoplastic biologic agent At least 1 week since prior concurrent hematopoietic growth factor At least 12 day since prior concurrent CYP3A4 inducer , include follow : Rifampin Rifabutin Carbamazepine Phenobarbital Phenytoin Hypericum perforatum ( St. John 's wort ) Efavirenz Tipranavir At least 7 day since prior concurrent CYP3A4 inhibitor , include follow : Azole antifungal ( e.g. , itraconazole ketoconazole ) Clarithromycin Erythromycin Diltiazem Verapamil HIV protease inhibitor ( e.g. , indinavir , saquinavir , ritonavir , atazanavir , nelfinavir ) Delavirdine No 1 concurrent antihypertensive agent No concurrent major surgery No concurrent antithrombotic antiplatelet agent , include follow : Warfarin Heparin Low molecular weight heparin Acetylsalicylic acid ( aspirin ) Ibuprofen Other nonsteroidal antiinflammatory drug No concurrent medication treatment hypertension No concurrent investigational drug No concurrent anticancer agent , include chemotherapy , radiotherapy , immunotherapy , biologic therapy</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>